ImmunityBio, Inc. IBRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 99.3%-0.7pp | 100%0.0pp | 100%0.0pp | 100%— | |
| Operating margin | -226%+2,108pp | -2,334.2%+55,905pp | -58,239.5%+88,135pp | -146,374.2%-111,012pp | |
| Net margin | -310.2%+2,495pp | -2,804.8%+90,957pp | -93,761.4%+79,808pp | -173,569.6%-136,440pp | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.2× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 5.1×+1.7× | 3.4×-1.7× | 5×+4.8× | 0.3×-0.6× | |
| Per Share | |||||
| Book value per share | -$0.54+22.1% | -$0.70+39.5% | -$1.15-3.2% | -$1.12-79.8% | |
| Valuation | |||||
| Market capitalization | $1.95B+4.3% | $1.87B-44.5% | $3.37B+64.6% | $2.05B-15.4% | |
| Price / sales | 17.2×-110× | 126.8×-5,288× | 5,414.4×-3,113× | 8,527×+5,937× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ImmunityBio, Inc.'s profit margins?
- ImmunityBio, Inc. (IBRX) runs a 99.3% gross margin and a -185.4% operating margin, with a -606.2% net margin.
- Where do ImmunityBio, Inc.'s ratios come from?
- Every ratio is computed from ImmunityBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
